Akebia Therapeutics (Nasdaq: AKBA) granted a stock option inducement award to one newly hired employee on August 31, 2026. The option covers an aggregate of 8,400 shares of Akebia common stock at an exercise price of $0.92 per share, equal to the closing price on the grant date. The award was approved under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly thereafter, subject to continued service, and have a 10-year term under Akebia’s inducement award program and stock option agreement.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
Recent insider data recorded Net Selling of 56,019 shares. That platform context adds an ownership s...
Analysis
Recent insider data recorded Net Selling of 56,019 shares. That platform context adds an ownership signal to this routine grant disclosure, while the four-year vesting schedule and continued-service condition remain the principal terms to monitor.
Key Figures
Shares Granted:8,400 sharesExercise Price:$0.92 per shareVesting Period:4 years+3 more
6 metrics
Shares Granted8,400 sharesOne newly hired employee; August 31, 2026 grant
Exercise Price$0.92 per shareEqual to the closing price on the grant date
Vesting Period4 yearsSubject to continued employee service
First Vesting Tranche25%Vests on the first anniversary of the grant date
Remaining Vesting Tranche75%Vests quarterly after the first anniversary
Option Term10-year termSubject to the inducement award program and option agreement
Options covering 125,600 shares were granted to three new employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent reactions were mixed: the earnings decline aligned with negative news, while clinical and inducement announcements showed divergent or limited directional alignment.
Key Terms
nasdaq listing rule 5635(c)(4)
1 terms
nasdaq listing rule 5635(c)(4)regulatory
"The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on August 31, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $0.92 per share, which is equal to the closing price of Akebia’s common stock on the grant date.The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with Akebia.Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
What stock options did Akebia Therapeutics (AKBA) grant on August 31, 2026?
Akebia granted a stock option covering 8,400 shares of its common stock to one newly hired employee. According to Akebia, the options were issued as an inducement award under its program and Nasdaq Listing Rule 5635(c)(4).
What is the exercise price of the new Akebia Therapeutics (AKBA) inducement stock options?
The exercise price of the inducement stock options is $0.92 per share. According to Akebia, this price equals the closing price of its common stock on the August 31, 2026 grant date.
How do the Akebia Therapeutics (AKBA) inducement stock options vest for the new employee?
The inducement stock options vest over four years. According to Akebia, 25% of the shares vest on the first anniversary of the grant date, with the remaining 75% vesting quarterly thereafter, subject to continued service.
What is the term of the Akebia Therapeutics (AKBA) inducement stock options granted in 2026?
Each inducement stock option has a 10-year term. According to Akebia, the options are subject to the company’s inducement award program and a stock option agreement that governs the specific terms and conditions.
Why did Akebia Therapeutics (AKBA) use Nasdaq Listing Rule 5635(c)(4) for this stock option grant?
Akebia used Nasdaq Listing Rule 5635(c)(4) because the grant is a material inducement to the employee entering into employment. According to Akebia, this rule allows equity awards outside stockholder-approved plans for such hiring incentives.
How many Akebia Therapeutics (AKBA) shares are covered by the 2026 inducement award?
The 2026 inducement award covers options to purchase 8,400 shares of Akebia common stock. According to Akebia, these shares are subject to vesting over four years and a 10-year option term.
